272 Shares in Astera Labs, Inc. (NASDAQ:ALAB) Bought by Geneos Wealth Management Inc.

Geneos Wealth Management Inc. bought a new stake in Astera Labs, Inc. (NASDAQ:ALAB) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 272 shares of the company’s stock, valued at approximately $36,000.

Other institutional investors also recently made changes to their positions in the company. ORG Wealth Partners LLC purchased a new position in Astera Labs in the 4th quarter valued at approximately $42,000. Hollencrest Capital Management purchased a new position in shares of Astera Labs in the third quarter valued at $26,000. GAMMA Investing LLC increased its position in shares of Astera Labs by 78.3% in the fourth quarter. GAMMA Investing LLC now owns 510 shares of the company’s stock valued at $68,000 after buying an additional 224 shares in the last quarter. Berbice Capital Management LLC acquired a new position in shares of Astera Labs during the 4th quarter worth $86,000. Finally, US Bancorp DE purchased a new stake in shares of Astera Labs in the 3rd quarter worth about $46,000. 60.47% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Astera Labs news, Director Manuel Alba sold 11,000 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $117.50, for a total value of $1,292,500.00. Following the completion of the sale, the director now owns 456,863 shares of the company’s stock, valued at $53,681,402.50. This trade represents a 2.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stefan A. Dyckerhoff sold 50,000 shares of Astera Labs stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $89.70, for a total transaction of $4,485,000.00. Following the sale, the director now owns 129,617 shares in the company, valued at $11,626,644.90. This represents a 27.84 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,690,452 shares of company stock valued at $167,581,256.

Analysts Set New Price Targets

A number of brokerages have issued reports on ALAB. Stifel Nicolaus lifted their target price on shares of Astera Labs from $100.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Roth Mkm lifted their price objective on Astera Labs from $80.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Morgan Stanley lowered their target price on Astera Labs from $142.00 to $114.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 28th. Citigroup began coverage on Astera Labs in a report on Monday, November 18th. They issued a “buy” rating and a $120.00 price target for the company. Finally, JPMorgan Chase & Co. increased their price objective on Astera Labs from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $107.42.

Astera Labs Price Performance

Shares of NASDAQ ALAB opened at $101.42 on Friday. The firm has a fifty day moving average of $122.46 and a 200-day moving average of $80.02. Astera Labs, Inc. has a 52-week low of $36.22 and a 52-week high of $147.39.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. The firm had revenue of $113.10 million during the quarter, compared to the consensus estimate of $97.50 million. Astera Labs had a negative return on equity of 15.57% and a negative net margin of 30.69%. The business’s revenue for the quarter was up 47.1% on a year-over-year basis. As a group, analysts anticipate that Astera Labs, Inc. will post -0.45 EPS for the current fiscal year.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.